On the 21 february in European Parliament was held an international conference EU-Russia “Released-activity phenomenon: application prospectives in medicine and technology”.
An international group of scientists from France, UK, USA, Norway and Russia in parallel with each other for more than 20 years developed the idea of Professor Oleg Epstein from Russia and came to common results that confirm it. Yesterday scientists met the members of the European Parliament and discussed the legislative future of Released-activity phenomenon and application prospectives in medicine and technology.
Professor Oleg Epstein, who opened the conference said that released-active drugs, and especially released-active antibodies, open up new opportunities in medicine. Modifying effect of them on the original substance can be used in technology to develop new materials, especially in nanotechnology.
Conference host, member of European ParliamentBill Etheridge said: “This is an example of successful cooperation between Russia and the EU in the period of complicated relations between our countries. In the era of information society, when communication links actually erase state borders this is an excellent example of how scientific activity can become a unifying motive, a point of contact and interaction in the establishment of political cooperation between the countries of Europe and the Russian Federation. We, as politicians, should encourage and develop such contacts between scientists of our countries to solve the global issues of humanity in the field of public health maintenance”.
Sebastian Johnston, professor of Respiratory Medicine & Allergy at the National Heart and Lung Institute, Imperial College London said that products containing released-active antibodies to immune proteins may possess antiviral/anti-inflammatory effects which may make them attractive for treatment of illnesses induced by rhinoviruses, such as asthma exacerbations.
The world-famous French Professor Jean-Claude Chermann, who discovered the human immunodeficiency virus, confirms the findings of his British colleague: «released-active antibodies can potentially be used as a part of combined therapy of viral infections including those caused by viral strains resistant to standard medicines».
Expert in experimental diabetics professor Bernard Portha noted that complex drug containing released-active antibodies to endothelial NO synthase and insulin receptor beta subunit, is effective to significantly improve glucose homeostasis.
Member of EP David Coburn said from Scotland said: «Innovations often face difficulties that are associated not only with the novelty of study approach, but also with its implementation, and often – with untimely acceptance by the scientific community, because breakthrough technologies usually transform the existing paradigm of scientific knowledge. The history of science is full of examples when novel achievements have been ignored for decades before their acknowledgement, let alone implementation. Now we face a lot of medical challenges that require urgent solutions, since they affect human life and health. We should fully support all the promising breakthroughs, with adequate attention payed to the quality of the related work, without doubt. There is solid scientific evidence of the relevance of research work carried out in the area of ultra-high dilutions of substances, despite the fact that understanding of the underlying processes is still difficult. We as politicians should support these extraordinary investigations. The main thing I see here is that Russians and west work together and that’s great”.
Senator Jean-Claude Mokeni said that he had always supported Russia, that’s why I’m glad that Russian scientists participate in the evolution of science.
Member of EP France Jamet said: «It was a very interesting conference. Diabetes is a disease that is well-known for a long time and I’m happy that nowadays there are new ways to deal with it using released-active drugs. Also politicians should make their contribution in the development of scientific cooperation. And today I can say for sure that cooperation between Russia and European Union exists and it is continued».
Dr. Mikhail Putilovsky told about results of clinical investigations sponsored by Materia Medica Holding. During the last 20 years in collaboration with the leading International Research institutes Materia Medica has created biotechnological platform based on the technologicaly processed antibodies. It has already resulted in a number of innovative drugs for treatment of various diseases including infections, diabetes, urological and neurological disorders.
As a result of the conference EP deputies signed a communiqué stating that «today humankind faces global problems in public health protection and the conference participants believe that the presented scientific data on the released-activity phenomenonare convincing. The field itself is relevant and certainly should be developed further as a promising and potentially breakthrough technology.